Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients.
BACKGROUND
Recent study has shown that overt hypothyroidism (oHT) is associated with increased plasma osteoprotegerin (OPG) levels.


OBJECTIVE
Our objective was to examine the plasma OPG level alteration before and after levothyroxine (L-T4) treatment in oHT and subclinical hypothyroidism (sHT).


METHODS
The study subjects included oHT and sHT patients and healthy individuals (20 subjects in each group).


METHODS
All patients were given L-T4 therapy to maintain a euthyroid state. Plasma OPG concentration was measured in duplicate by a sandwich ELISA.


RESULTS
Plasma OPG levels in oHT and sHT before treatment were significantly higher than levels in controls (P < 0.01). After normalization of thyroid function, OPG levels in both groups decreased markedly (P < 0.01). The absolute changes in OPG showed a significant positive correlation with the changes in TSH (P < 0.05) and negative correlation with the changes in endothelium-dependent arterial dilation (P < 0.01) in hypothyroid patients during the course of treatment.


CONCLUSIONS
OPG may be involved in the development of vascular dysfunction in hypothyroid patients.
Guang-da
Xiang
X
Department of Endocrinology, Wuhan General Hospital of Guangzhou Command, Wuluo Road 627, Wuhan 430070, Hubei Province, People's Republic of China. Guangda64@hotmail.com
Hui-ling
Sun
S
Zhi-song
Cheng
C
Lin-shuang
Zhao
Z
D000328:Adult; D002784:Cholesterol / Q000097:blood; D004730:Endothelium, Vascular / Q000503:physiopathology; D005260:Female; D006023:Glycoproteins / Q000097:blood*; D020249:Hormone Replacement Therapy; D006801:Humans; D007037:Hypothyroidism / Q000097:blood* / Q000188:drug therapy*; D017270:Lipoprotein(a) / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear / Q000097:blood*; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood*; D013972:Thyrotropin / Q000378:metabolism; D013974:Thyroxine / Q000627:therapeutic use*; D014664:Vasodilation / Q000502:physiology
D006023:Glycoproteins; D017270:Lipoprotein(a); D008077:Lipoproteins, LDL; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506030:TNFRSF11B protein, human; D013972:Thyrotropin; D002784:Cholesterol; D013974:Thyroxine